Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
出版年份 2014 全文链接
标题
Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
作者
关键词
Immunotherapy, Non-small-cell lung cancer, L-BLP25, Anti-CTLA4, Anti-PD1/PDL1
出版物
Current Oncology Reports
Volume 16, Issue 9, Pages -
出版商
Springer Nature
发表日期
2014-07-16
DOI
10.1007/s11912-014-0400-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.
- (2014) Edward B. Garon et al. CLINICAL CANCER RESEARCH
- Recent Clinical Advances in Lung Cancer Management
- (2014) David H. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma
- (2012) S. P. Malkoski et al. CLINICAL CANCER RESEARCH
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
- (2011) Yi-Long Wu et al. BMC CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lung Cancer Vaccines
- (2011) Ronan J. Kelly et al. CANCER JOURNAL
- Active immunotherapy for non-small-cell lung cancer: moving toward a reality
- (2011) Cesar A Perez et al. Expert Review of Anticancer Therapy
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
- (2011) W. J. Curran et al. JNCI-Journal of the National Cancer Institute
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells
- (2011) D. Raina et al. MOLECULAR CANCER THERAPEUTICS
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- (2010) Rodryg Ramlau et al. Journal of Thoracic Oncology
- Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer
- (2010) Katsuhiko Shimizu et al. Journal of Thoracic Oncology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
- (2009) Enrico Ruffini et al. ANNALS OF THORACIC SURGERY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Transforming growth factor beta (TGF-β) and inflammation in cancer
- (2009) Brian Bierie et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer
- (2008) Elia Neninger Vinageras et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now